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Abstract - General anesthesia enables surgery, 
with anesthesia machines being the 
predominant tool to do so. However, these 
machines are hard to maintain, costly, and 
require significant supporting infrastructure. 
The current design of anesthesia machines 
demands the disposal of anesthetic gases at a 
rate equal to fresh oxygen entering the system. 
This causes several orders of magnitude more 
anesthetic vaporized than needed, yielding 
negative economic and environmental impact.  
To address this, we propose utilizing the porous 
surface of activated charcoal to absorb and 




Anesthesia machines and systems are at the center 
of surgical care.  Since their initial conception, the 
design and technology of anesthesia machines has 
become fine-tuned and perfected for the standard 
operating room.  However, the demand for 
anesthetic care has grown tremendously in areas 
outside the hospital and the anesthesia machine has 
not been able to keep pace.  Within the United 
States, the economic realities of health care and 
demands have pushed access from in-hospital to 
outpatient settings[1].  Globally, underdeveloped 
countries have been unable to match the pace of 
improved outcomes in anesthesia seen in the 
developed world[2].  These shifts in anesthesia 
care have led to a strikingly high incidence of 
preventable anesthesia-related mortality outside 
the hospital[3]–[5].  While there are various 
contributing factors to this mortality, the 
anesthesia machine remains a predominant factor 
in being unable to meet these new needs[2], [6], 
[7].   
 
In outpatient clinics and small-office practices, the 
large migration from hospitals to office-based 
anesthesia has not been accompanied with the 
same adherence of safety standards.  This lack of 
safety comes largely in the form of deficiencies in 
equipment and monitors.  With the high capital 
costs of anesthesia machines, large size, and 
necessity for high pressure oxygen and scavenging 
lines, many clinicians turn to potent intravenous 
anesthetics without the presence of ventilation 
equipment or monitoring[8].  In the event that a 
patient exhibits respiratory depression or develops 
an airway obstruction or apnea, the likelihood of a 
successful resuscitation is be markedly reduced, 
and the effects of this have already been 
demonstrated.  The ASA Closed Claims analysis 
has shown that office-based claims had more than 
tripled the number of deaths, 67% versus 21%, 
compared to their hospital counterparts. 
Furthermore, almost half of these claims were 
deemed preventable by better monitoring[9]. In a 
Figure 1 - Migration of anesthesia-related procedures from 1981-
2005.  Current statistics show that majority of outpatient 
procedures are now performed outside the hospital. 
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more controversial study, the frequency of 
incidence and death was found to be an order of 
magnitude higher in the small-office compared to 
the hospital[10].  With outpatient surgery rapidly 
migrating to non-hospital settings, this 
discrepancy in quality of care is becoming 
increasingly concerning (Figure 1)[1]. 
 
Anesthesia in low-resource areas is facing similar 
issues.  Because the healthcare systems and the 
means to support complex technology in the 
developing world is often inadequate, many 
countries turn to importing their equipment despite 
it being often ill-suited for the environment.  For 
many countries, there is an distinct emphasis on 
healthcare equipment funded by both international 
donors and foreign governments, with donations 
comprising nearly 80% of the incoming 
equipment[11].  However, because of 
sophistication of these devices, and the expertise 
and parts required to maintain them, anesthesia 
machines are particularly prone to fall by the way 
side, with as little as 10% of these machines ever 
becoming operational[12].  This makes operating 
facilities incredibly scare for these low resource 
areas with the estimated number of operating 
rooms per 100,000 people being more than 25 
times less than high-income regions[13]. 
Additionally, the operating rooms that do exist in 
developing countries encounter significantly more 
adverse events and mortality.  In the United States, 
the estimated mortality risk of anesthesia was 0.82 
in 100,000 between 1999-2005[14].  
Comparatively, the risk of death due to anesthesia 
was 3.14 in 10,000 for developing countries, 
nearly 40 times higher[5].  Developing anesthesia 
equipment that targets these issues could improve 
outcomes significantly. 
 
Future advancements to the anesthesia machine 
will need to both increase device longevity and 
reduce capital and operational costs to encourage 
adoption.  After surveying the components and 
technologies used in anesthesia machines, the 
infrared spectrophotometer used to monitor 
anesthetic gas concentrations becomes a prime 
target for redevelopment.  The infrared 
spectroscopy represents a large portion of the 
capital costs in anesthesia machines due to the 
complex and fragile optics involved.  Creating an 
alternative to this technology would greatly 
expand access to adequate anesthesia care.  
Another area of potential improvement in the 
anesthesia machine targets how anesthetic gases 
are recirculated.  Currently anesthetic gases must 
be removed from the system at the same rate as 
incoming oxygen, despite anesthetics being 
largely unmetabolized by the patient.  Because of 
this design choice, over the course of a 2 hour 
procedure, more than an order of magnitude more 
anesthetic is vaporized than needed.  Developing a 
method to conserve these anesthetic gases would 
decrease the overall cost, and even potentially 
remove the need for scavenging systems installed 
in hospitals.  Lastly, creating an automated 
anesthesia machine that monitors patient vital 
signs and adjusts the delivery of anesthesia 
accordingly could significantly aid clinicians who 
are not as highly trained in anesthesia care.  While 
all of these aspects are being investigated, the 
focus on this paper will be the development of a 
medical device to reuse anesthetic gases. 
 
To address the poor efficiency of anesthetic use, an 
understanding of current anesthesia machines is 
essential.  Current anesthesia machines are divided 
into four breathing circuit types: open, semi-open, 
semi-closed, and closed.  These circuit types refer 
to whether or not rebreathing occurs in the system, 
specifically where semi-closed and closed system 
do have rebreathing.  Most modern anesthesia 
machines used in the developed world are semi-
closed systems, introducing a rebreathing circuit to 
reuse the anesthetic gas to a partial degree.  
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However, anesthetic still must be removed from 
the system at the same rate as incoming fresh 
oxygen and remains non-ideal.  Even worse are the 
anesthesia systems found in the developing world, 
most often being open or semi-open breathing 
circuits which do not incorporate any mode of 
rebreathing and as a result make no attempt at 
reusing anesthetic.  Designing a system that can be 
used in both of these types of systems would 
address the largest pool of machines. 
 
An inspiratory-expiratory loop anesthesia machine 
add-on capable of reflecting the anesthetic gas 
would fit this criteria.  Conveniently, the porous 
surface of activated charcoal makes it a potential 
medium to absorb and desorb anesthetic gases, and 
has already been shown effective in sequestering 
anesthetic gases for those susceptible to malignant 
hyperthermia[15].  To explore the suitability of 
activated charcoal in reflecting anesthetic gases, 
we have created an anesthesia machine add-on 
prototype with the intended use of reducing the 




II.  METHODS 
 
A. Feasibility Testing 
To test the feasibility of using activated charcoal 
as a reflecting medium, a crude prototype was 
created containing activated charcoal.  
Specifically, 5 liter per minute flow of oxygen 
and 5% isoflurane (Piramal Healthcare Limited, 
Andhra Pradesh, India) was delivered through a 
cylindrical vessel containing 42 grams of 
activated charcoal (Oxpure 1220C-75, Oxbow 
Activated Carbon, West Palm Beach, FL) until 
0.5% isoflurane pushed through the charcoal.  
Flow was then reversed through the vessel at 2 
liters per minute with pure oxygen and the 
concentration of isoflurane leaving the vessel was 
monitored using a standard side stream infrared 
gas bench (Datex-Ohmeda, Helsinki, Finland). 
 
B. Prototype Device Design 
After promising results, a more advanced two 
chamber housing was 3D printed using UV-cured 
MED-10 biocompatible plastic.  The design allows 
for bypass of inhaled/exhaled gas to either pass 
freely without interference or through a cartridge 
containing 12 grams of activated charcoal (Oxpure 
1220C-75, Oxbow Activated Carbon, West Palm 
Beach, FL)(Figure 2). 
 
An MCU monitors and controls a variety of 
sensors and components associated with the device 
based off a custom PCB (Figure 3).  A gear 
controlled by a 12V small reduction stepper motor 
controls what proportion of the gas flow is directed 
through each chamber.  To determine inspiratory 
or expiratory flows, multiple differential pressure 
sensors (MPXV7002DP Integrated Silicon 
Pressure Sensor On-Chip Signal Conditions, 
Temperature Compensated and Calibrated, NXP 
Semiconductors, Austin, TC; DLVR-L01D Low 
Voltage Digital Pressure Sensor, All Sensors, 
Morgan Hill, CA) in conjunction with Respironics 
NICO capnograph flow module.  The MCU also 
received oxygen, carbon dioxide, and anesthetic 
Figure 2 - 3D rendering of the prototype housing.  The design 
includes a main body with two chambers, one of which contains a 
charcoal cartridge.  This is contained with an end cap.  Internally, 
a gear with a semicircle opening directs flow. 
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agent concentrations from a standard infrared gas 
bench (Datex-Ohmeda, Helsinki, Finland).  Using 
the anesthetic concentration measured from the 
infrared gas bench and a set concentration input by 
the user, a basic feedback loop changed the 
position of the gear to meet the anesthetic 
requirements.  Additionally, alarms were included 
and displayed on an LCD screen in the event of 
high or low anesthetic agent concentration, low 
oxygen concentration, and low carbon dioxide 
concentration (possible apnea).  The MCU was 
programmed to saturate the charcoal during 
anesthesia induction, and run primarily on the 
reflected gas during maintenance (Figure 4). 
 
III.  RESULTS 
 
A. Feasibility Testing 
Isoflurane was released at concentrations suitable 
for anesthesia maintenance for a significant 
amount of time, approximately 10 minutes (Figure 
5).   
 
 
Figure 5 - The observed concentration of isoflurane leaving the 
vessel containing 40 grams of saturated activated charcoal as the 
flow was reversed at 2 liters per minute. The activated charcoal 
(black) allowed for the gradual released of isoflurane compared to 
the control (red) containing no activated charcoal. 
 
Figure 6 - The observed concentration of isoflurane during 
ventilation between the vessel of 10 grams of activated charcoal 
and the test lung. Similar to Figure 5, the activated charcoal (grey) 
allowed for the gradual released of isoflurane compared to the 
control (pink) containing no activated charcoal. A running average 
is shown for both the activated charcoal (black) and control (red). 
Ventilation was also tested to investigate more 
dynamic conditions where the device was 
ventilated with a test lung (Figure 6).  Once 
saturated, the activated charcoal had absorbed 
approximately 60% of its total weight in 
Figure 3 - MCU controller for the anesthetic reflector.  Consists 
of a keypad, LCD screen, stepper motor and driver, and various 
differential pressure sensors. 
Figure 4 - Schematic of device during use.  During induction, the 
device will alternate between open and filter chamber during 
inspiration and expiration respectively (Phases 1-2). Once the 
filter is saturated, all inspiratory and expiratory gas will be 
passed through that chamber (Phase 3). 
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isoflurane, and was capable of repeatedly 
reflecting 10% of its total weight in isoflurane or 
about 3.2 mL of liquid isoflurane.  This volume of 
isoflurane capable of being reflected is the 
equivalent of anesthesia maintenance at 1 MAC 
for 1 hour at a fresh gas flow rate of 1 liter per 
minute. 
 
B. Prototype Device Design 
A prototype was successfully created and was 
capable of performing the basic desired functions.  
Specifically, inspiratory and expiratory flows were 
detected and a basic “bang-bang” feedback control 
was implemented to achieve the desired 
concentration.  Future iterations will focus on 
increasing the speed of the valve control as well as 
more controllable PID feedback control. 
 
IV.  DISCUSSION 
 
Activated carbon has been shown to readily 
absorb and release anesthetic gases. Creating a 
system using this material would allow for the 
implementation of an activated carbon reflector 
that absorbs, holds, and releases anesthetic gases 
back to the patient. Not only would this remove 
the need for an anesthetic scavenging system, but 
it would also significantly decrease the cost of 
anesthetic maintenance by reducing the amount 
of gas vaporized. Preliminary data has shown that 
40-mesh activated carbon can capture anesthetic 
gases and release them with reversed flow at a 
concentration high enough for sedation. By 
combining this material with a novel breathing 
circuit design, we will remove the need for a 
scavenging system and expand the environments 
in which anesthesia can be used.   Success in this 
research will ultimately reduce the cost, 
infrastructure, and expertise needed to deliver 
general anesthesia. By doing this, the global 
access to anesthesia and surgical will be greatly 
increased, reducing the suffering in the world. 
 
Future work will include further development and 
tuning of this technology, and incorporating it 
with other advances in the field of anesthesiology 
to create a novel anesthesia machine that 
addresses the needs in both the developing world 
and the emerging small-office anesthesia.  These 
will include better patient monitoring, reduced 
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